KOSDAQBiotech & Pharma261780

Aribiolab

₩5,290▲ 29.98%2026-11-18 close
Market Cap
₩153.2B
Turnover
₩72.1B
Volume
13.9M
Shares out.
29M
PER
—
PBR
12.3×
EPS
-₩464
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Vaccine pipeline expands as losses persist

Aribiolab is widening its research scope to a shingles vaccine in Phase 2 and neuroimmunology, yet on a disclosed basis its 2025 revenue was KRW 159 million against an operating loss of KRW 14.3 billion.

  1. 1

    On a disclosed basis, 2025 revenue fell 57.2% year on year to KRW 159 million, while the operating loss widened to KRW 14.3 billion.

  2. 2

    The operating loss narrowed to KRW 1.67 billion in the third quarter of 2026 from a year earlier, but the company has posted losses for five consecutive quarters since the third quarter of 2025.

  3. 3

    The shingles vaccine CVI-VZV-001 has completed its second dosing in Phase 2, with topline results due in the first quarter of 2027 and Phase 3 planned afterward.

  4. 4

    Aribiolab decided to acquire a KRW 10 billion convertible bond issued by Aribio, and Aribio agreed to invest KRW 15 billion in a KRW 18 billion rights offering, so the ownership structure is shifting.

  5. 5

    With net losses over the most recent four quarters, PER cannot be calculated, and the price-to-book ratio sits in a range with a large premium over net assets.

02

Business structure

Aribiolab is the vaccine and immunology specialist of the Aribio group, and it changed its name from Cha Vaccine Institute and listed under the current name in May 2026. Its most advanced pipeline is CVI-VZV-001, a recombinant shingles preventive vaccine.

In Phase 1 it confirmed safety and a 100% seroprotection rate, and in a Phase 2 study of 135 adults aged 50 and older it completed the second dose. The company plans to release topline results in the first quarter of 2027 before entering Phase 3.

The hepatitis B therapeutic vaccine CVI-HBV-002 significantly raised HBV-specific T-cell responses versus placebo in a Phase 2b study, and combination with siRNA therapies and expansion into preventive vaccines are under review.

The mRNA-based immuno-oncology candidate CTRNA-001 is a two-year national drug development project targeting head and neck squamous cell carcinoma first. A government-funded project is also developing the first domestic recombinant Japanese encephalitis vaccine.

The technology base is the in-house adjuvant platforms L-pampo and Lipo-pam, and Lipo-pam is the only domestic company technology listed in the CEPI vaccine adjuvant library. Commercialization centers on joint research with global vaccine developers, adjuvant supply and licensing.

Domestically, the company signed an MOU with Samjin Pharm on joint development and commercialization. A July 2026 report said the articles of incorporation were amended to add cosmetics manufacturing and sales to the business purpose, as a way to broaden revenue.

However, disclosed revenue is only in the KRW 100 million range annually, so the vaccine-focused business has not yet translated into meaningful sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩3.4B—
2025Q4₩0-₩5.4B—
2026Q1₩200M-₩1.7B−985.0%
2026Q2₩0-₩2.5B—
2026Q3₩0-₩1.7B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩200M-₩6.5B-₩6.7B−3604.4%−20.1%83.0%
2023₩300M-₩6.4B-₩1.7B−2182.5%−4.9%27.4%
2024₩400M-₩7.7B-₩10.1B−2076.4%−36.6%70.4%
2025₩200M-₩14.3B-₩16B−8997.2%−135.3%151.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Across the annual disclosed results, revenue rose from KRW 179 million in 2022 to KRW 294 million in 2023 and KRW 371 million in 2024, then fell to KRW 159 million in 2025. Of the 2022 to 2025 period, 2024 was the largest year and 2025 the smallest, and 2025 revenue fell 57.2% year on year.

The operating loss was KRW 6.47 billion in 2022, KRW 6.42 billion in 2023, KRW 7.7 billion in 2024 and KRW 14.3 billion in 2025, so the loss narrowed in 2023 and widened in 2024 and 2025. The company has posted losses for four consecutive years from 2022 through 2025.

The operating margin was -8,997.2% in 2025, showing that revenue does little to offset the operating loss.

Net loss attributable to controlling shareholders was KRW 6.72 billion, KRW 1.75 billion, KRW 10.1 billion and KRW 16 billion for 2022 through 2025, and net loss including non-controlling interests was disclosed separately at KRW 6.72 billion, KRW 1.75 billion, KRW 10.1 billion and KRW 16 billion for the same years.

The debt-to-equity ratio rose from 83.0% in 2022 and 27.4% in 2023 to 70.4% in 2024 and 151.1% in 2025. At end-2025, total equity was KRW 11.9 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 17.9 billion.

Operating cash flow was -KRW 5.19 billion in 2022 and widened to -KRW 11 billion in 2025.

Quarterly, the operating loss was KRW 3.42 billion in the third quarter of 2025 and KRW 5.39 billion in the fourth quarter, narrowed to KRW 1.71 billion in the first quarter of 2026, rose to KRW 2.46 billion in the second quarter and narrowed to KRW 1.67 billion in the third quarter.

Net loss attributable to controlling shareholders was KRW 3.76 billion in the third quarter of 2025 and KRW 1.96 billion in the third quarter of 2026, and totaled KRW 12.6 billion over the most recent four quarters.

Apart from KRW 173 million in the first quarter of 2026, no quarterly revenue appears in the disclosed results. Funding has filled part of the gap: Aribio agreed in September 2026 to invest KRW 15 billion in Aribiolab's KRW 18 billion third-party rights offering. The cost items behind the widening losses can be traced in the periodic report's expense breakdown.

05

Industry analysis

The company says domestic recombinant shingles vaccines are entirely imported, which gives localization significant meaning. Recent epidemiological studies linking shingles vaccination to a lower risk of dementia have drawn attention to the relationship between immunity and neurodegenerative disease.

That link, however, does not directly prove a preventive effect against Alzheimer's disease. Within the same group, Aribio completed the global Phase 3 dosing of its oral Alzheimer's drug AR1001 in 1,535 patients across 13 countries.

Topline results for AR1001 are slated for disclosure at CTAD 2026 in Boston on November 16, 2026. Among vaccine developers, Aribiolab's differentiator is its adjuvant platform, and its listing in the CEPI library works as an external technology credential.

SK Bioscience (SK Bioscience), a listed company focused on vaccines in the same sector, can serve as a comparison point. The gap in revenue scale and clinical stage is wide, so the competitive position will depend on clinical results and whether licensing deals are completed. The room for domestic supply of shingles vaccines is one reason the clinical outcome carries weight.

06

Outlook

The nearest checkpoint is the topline result of the shingles vaccine's Phase 2 study. The company plans to release topline results in the first quarter of 2027 and then enter Phase 3. The hepatitis B therapeutic vaccine is under review for combination with siRNA therapies and for expansion into preventive use.

The mRNA immuno-oncology candidate research runs over two years and incorporates AI-based drug design. On commercialization, the company is pursuing joint development and licensing with global companies based on its adjuvant platform.

On revenue, the company has said the need to expand sales grows from 2027, and it is reviewing businesses beyond vaccine R&D that could generate sales. On governance, Aribio agreed to acquire a convertible bond from Aribiolab, and if the conversion right is exercised the two companies would hold shares in each other.

Once the rights offering payment is completed, the largest shareholder is set to change to Aribio. Some observers are also watching for a possible merger between the two companies.

However, reports note that after the largest-shareholder change there are constraints on a near-term merger, and an absorption merger would take eight to nine months or more. Depending on the group's AR1001 Phase 3 results, valuation and future merger and listing strategies could change.

07

Valuation

PER
—
PBR
12.3×
ROE
-91.5%
EPS
-₩464
BPS
₩373
Dividend per share
₩0

With net losses over the most recent four quarters, PER cannot be calculated, so earnings-based multiples offer limited comparison. The price-to-book ratio sits in a range with a large premium over net assets, meaning market expectations weigh heavily relative to book capital.

Total equity of KRW 11.9 billion at end-2025 was smaller than the KRW 16 billion net loss attributable to controlling shareholders for the same year, which frames the financial cushion. Dividends are virtually absent, so shareholder-return comparisons are limited.

The company said the price of the convertible bond reflected the success probability of AR1001 Phase 3 and expectations for commercialization. Because the company is loss-making, comparisons rely mainly on net-asset-based measures rather than earnings-based ones. The share price can move on events such as the AR1001 results and governance changes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Clinical pipeline progress

The shingles vaccine CVI-VZV-001 confirmed safety and a 100% seroprotection rate in Phase 1 and has completed Phase 2 dosing. Topline results due in the first quarter of 2027 will determine whether Phase 3 begins.

The hepatitis B therapeutic vaccine also raised T-cell responses significantly versus placebo in a Phase 2b study.

External validation of the platform

Lipo-pam is the only domestic company technology listed in the CEPI vaccine adjuvant library. Based on that listing, the company intends to pursue joint research, adjuvant supply and licensing with global vaccine developers. Whether licensing deals are actually concluded is the checkpoint for the commercial value of the platform.

Narrowing losses

The third-quarter 2026 operating loss of KRW 1.67 billion narrowed from a year earlier. Net loss attributable to controlling shareholders was KRW 1.96 billion in the third quarter of 2026, smaller than KRW 3.76 billion in the third quarter of 2025.

The first-quarter 2026 operating loss of KRW 1.71 billion was also below the KRW 5.39 billion recorded in the fourth quarter of 2025, showing a quarterly easing trend.

09

Bear factors

Thin revenue base

Revenue in 2025 fell 57.2% year on year to KRW 159 million, against an operating loss of KRW 14.3 billion. The operating margin of -8,997.2% shows that sales barely offset the losses. Operating cash flow of -KRW 11 billion was the largest outflow in the 2022 to 2025 period. The company has said the need to expand sales grows from 2027.

Persistent losses and financial strain

The company has posted losses for four consecutive years from 2022 through 2025, and for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. Net loss attributable to controlling shareholders over the most recent four quarters totaled KRW 12.6 billion. The debt-to-equity ratio rose to 151.1% in 2025 from 27.4% in 2023, with total liabilities of KRW 17.9 billion.

Dependence on group outcomes and governance

Depending on the group's AR1001 Phase 3 results, valuation and future merger and listing strategies could change. Because the largest-shareholder change is tied to convertible bond and rights offering transactions within the group, the business direction may depend on group strategy. The neuroimmunology and anti-aging areas are at an early stage, so verifying results will take time.

10

Risk factors

Financing and funding

Operating cash outflow widened to -KRW 11 billion in 2025, with total equity of KRW 11.9 billion and total liabilities of KRW 17.9 billion. The company plans to fill funding needs for its shingles vaccine trial and follow-on R&D through rights offerings and other capital raises. Depending on the size and timing of these raises, shareholder dilution may follow.

Clinical and technology risk

The shingles vaccine can enter Phase 3 only after topline results are released in the first quarter of 2027. The mRNA immuno-oncology program is in a two-year candidate-identification phase, and the Japanese encephalitis vaccine is also an early-stage project.

The hepatitis B therapeutic vaccine is still at the combination-review stage, so the path from clinical results to business value is long.

Governance and related-party transactions

Cross-shareholding is forming through intra-group convertible bond purchases and participation in rights offerings, so transaction terms and the independence of decision-making need to be examined. Some observers note that the governance reshuffle could lead to a merger between the two companies.

On listing matters, a report says the revenue-based grace period burden for companies listed through the technology special listing route is becoming real.

11

What to watch next

  1. After November 16, 2026 (right after the CTAD 2026 presentation)

    The main AR1001 Phase 3 results affect the group's valuation and its merger and listing strategy. After disclosure, the checkpoint is whether Aribiolab's governance and R&D direction shift.

  2. Date to be determined (disclosure of rights offering payment completion)

    Once payment is complete, the largest shareholder changes to Aribio and the ownership structure is fixed. Afterward, the direction of R&D cooperation and any merger discussions between the two companies will become visible.

  3. First quarter of 2027

    Topline results of the Phase 2 study of shingles vaccine CVI-VZV-001 will determine whether Phase 3 begins, making this a key checkpoint.

  4. By end-March 2027 (deadline for the 2026 annual report)

    Annual 2026 revenue, operating loss and cash flow will be confirmed in the periodic report. The segment revenue mix and expense breakdown can also be checked there.

  5. By May 15, 2027 (deadline for the Q1 2027 quarterly report)

    Q1 2027 revenue and operating loss will be disclosed in the periodic report, showing whether the narrowing trend continues.

12

Overall view

Aribiolab is broadening its pipeline with the completed Phase 2 dosing of its shingles vaccine, an mRNA immuno-oncology program and a Japanese encephalitis vaccine, and its platform has external validation through its CEPI library listing.

However, disclosed revenue in 2025 was only KRW 159 million while the operating loss widened to KRW 14.3 billion, and five consecutive quarters of losses plus KRW 12.6 billion in net loss attributable to controlling shareholders over the last four quarters highlight financial strain.

The third-quarter 2026 operating loss narrowed from a year earlier, a sign of easing, but the pace at which the business converts into sales remains a challenge.

Financially, operating cash outflows widened each year and the debt-to-equity ratio rose to 151.1% in 2025, so the company continues to rely on external funding such as rights offerings and convertible bonds.

On governance, the group is reshaping into a cross-shareholding structure through Aribio's bond purchase and rights offering participation, and a merger has been raised as a possibility.

Once the group's AR1001 Phase 3 results are released, governance and merger or listing strategies could shift, which is another variable. The next checkpoints are the first-quarter 2027 topline for the shingles vaccine and the revenue and operating loss structure in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. thebionews.net
  2. supple.kr
  3. etoday.co.kr
  4. fnnews.com
  5. newsprime.co.kr
  6. view.asiae.co.kr
  7. etoday.co.kr
  8. thebionews.net
  9. joongangenews.com
  10. alphabiz.co.kr
  11. newstopkorea.com
  12. weekly.hankooki.com
  13. bosa.co.kr
  14. sentv.co.kr
  15. cbci.co.kr
  16. hankyung.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis